Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients with other clinical manifestations of atherosclerotic cardiovascular ...

Overall, patients in the semaglutide arm had median and mean improvements in walking distance compared to placebo of 26 meters and 39.9 meters respectively, giving a statistically significant ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

This between-group difference produced an estimated treatment ratio of 1.13 for semaglutide (95% CI 1.06-1.21), corresponding, in absolute terms, to a median 26.4-meter improvement in maximum walking ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...